Japan briefs: Kyowa Kirin debuts Onglyza; Otsuka enrolls TB study, sets up new European

10 July 2013

Japanese drugmaker Kyowa Hakko Kirin (TY: 4151) revealed that it launched the type 2 diabetes drug Onglyza (saxagliptin hydrate), originated by US pharma major Bristol-Myers Squibb (NYSE: BMY) in Japan on July 9.

Onglyza provides a new option in the treatment of type 2 diabetes and is therefore expected to help healthcare professionals and patients to manage type 2 diabetes. The price is 110.2 yen ($1.09) for a 2.5mg tablet and 166 yen for a 5mg tablet.

Otsuka’s “ground-breaking” delamanid progam

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical